NTRA
Natera Inc
NASDAQ: NTRA · HEALTHCARE · DIAGNOSTICS & RESEARCH
$199.14
-3.06% today
Updated 2026-06-05
Market cap
$30.37B
P/E ratio
—
P/S ratio
12.14x
EPS (TTM)
$-1.61
Dividend yield
—
52W range
$132 – $256
Volume
1.5M
Natera Inc (NTRA) Financial Forecast & Price Target 2030
Research-backed projections from analyst consensus, management guidance, and sector analysis.
Research-backed NTRA price target 2030 projection accounting for share dilution, balance sheet debt, and time value of money.
Current price
$199.14
Today
Analyst consensus
$260.89
+31.01% · 12M
2030 Base
$178.39
-10.42% future
NPV today
$101.14
@ 13% WACC
19 analysts:
14 Buy3 Hold1 Sell
Management guidance
Natera raised FY2026 revenue guidance to $2.62B–$2.70B (midpoint $2.66B, implying 15.2–16.9% growth from $2.31B in 2025). CEO Stephen Chapman emphasized record test volumes, accelerating women's health and oncology adoption, and Japan market entry. No explicit guidance beyond 2026, but management signaled confidence in sustained high-volume growth and margin expansion through product mix improvement and international scale.
Sources: Management guidance, analyst consensus, sector analysishigh confidence
NTRA · Natera Inc · Revenue & price projection · 2023–2030E
Actual / 2030 target Projected revenue Base case price Bull to bear range
Bear case (2030)
$90.84
NPV today: $51.50
Base case (2030)
$178.39
NPV today: $101.14
Bull case (2030)
$441.05
NPV today: $250.05
WallStSmart.com
NTRA financial forecast · Research-backed projections
| Metric | 2025 | 2026 (E) | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) ★ |
|---|---|---|---|---|---|---|
| Revenue | $2.3B | $2.7B | $3.2B | $4.1B | $5.2B | $6.5B |
| Revenue growth | 35.9% | 15.2% | 20.8% | 28.3% | 27.0% | 23.8% |
| Net margin | — | -8.2% | -0.8% | 1.6% | 4.6% | 6.8% |
| EPS | $-1.52 | $-1.52 | $-0.18 | $0.45 | $1.65 | $2.98 |
| Diluted shares | — | 144M | 145M | 146M | 147M | 148M |
| Net debt | — | $804.92M | $1.68B | $2.80B | $4.23B | $6.00B |
| P/S multiple | — | 5.0x | 5.0x | 5.0x | 5.0x | 5.0x |
| Implied price (base) | — | $86.73 | $99.12 | $121.87 | $149.18 | $178.39 |
★ 2030E is the model's terminal target year. Implied price = (Revenue × P/S − Net debt) ÷ Diluted shares.
Scenario detail · Three drivers, three outcomes
| 2030E driver | Bear | Base | Bull |
|---|---|---|---|
| Revenue | $6.5B | $6.5B | $6.5B |
| P/S multiple | 3.0x | 5.0x | 11.0x |
| Diluted shares | 148M | 148M | 148M |
| Net debt | $6.00B | $6.00B | $6.00B |
| Implied P/E † | 31x | 60x | 148x |
| 2030 Price | $90.84 | $178.39 | $441.05 |
| NPV @ 13% | $51.50 | $101.14 | $250.05 |
† Implied P/E: Multiples remain elevated across all three scenarios because NTRA is valued primarily on revenue scale during its growth phase, not near-term earnings power. Lower P/E in the bear case reflects multiple compression, but the absolute level stays high since 2030E still represents a hypergrowth-to-mature transition year.
EV to per-share bridge · How we get to $178.39 base case
NTRA catalysts and risks
Growth catalysts
+ FDA approval of Signatera CDx as companion diagnostic in MIBC (May 2026) — enables reimbursement expansion and positions MRD as standard of care in oncology
+ EXPAND trial enrollment >2,000 patients for Fetal Focus single-gene NIPT — supports regulatory pathway and commercial scaling in prenatal segment
+ Japan market entry for Signatera MRD test — opens $2–3B international TAM with minimal cannialization
+ Continued clinical validation of MRD-guided treatment protocols (SINERGY, IMvigor011) — broadens addressable oncology market across solid tumors and hematologic malignancies
+ Gross margin expansion (guidance raised to 65%+ for 2026) — operating leverage as volumes scale and test mix shifts toward higher-margin oncology products
Key risks
- Profitability timeline remains uncertain — negative EPS of -$1.82 in 2026 guidance; path to positive earnings depends on sustained volume growth and operating expense control, not guaranteed by 2030
- Reimbursement volatility — MRD testing is nascent; payer adoption and coverage decisions for Signatera could slow if clinical utility questioned or pricing pressured
- Regulatory setbacks — FDA could impose additional labeling restrictions on companion diagnostics or require larger Phase IV trials, delaying revenue recognition
- Competitive pressure from sequencing leaders (Illumina, Guardant Health) and large diagnostics players (Quest, LabCorp) entering MRD and prenatal markets
- Insider selling signal — CEO and co-founder recent stock dispositions suggest possible near-term valuation concerns despite strong fundamentals
- Litigation risk — ongoing class action lawsuit (Wolf Haldenstein notice May 16, 2022) creates legal/settlement tail risk
Methodology · Natera Inc 2030 stock forecast model
Natera Inc 2030 price target is calculated using WallStSmart's research model. Revenue projections are derived from analyst consensus across 19 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts. The model is built on five core components:
| 1. Share dilution | Projected from per-ticker schedule of SBC + equity raise activity, compounding year by year (3% cumulative for NTRA by 2030) |
| 2. Net debt | EV minus net debt yields equity value; debt projected from capex cycle trajectory ($6.00B by 2030) |
| 3. Time value | NPV calculated using 13% WACC (CAPM: beta 1.567) |
| 4. Multiple framework | P/S compresses with scale: bear 3.0x / base 5.0x / bull 11.0x |
| 5. Scenario design | Bull/Base/Bear vary revenue, margin, shares, debt, and multiple independently |
WallStSmart research model · Not financial advice · Past performance is not indicative of future results · Last researched: May 20, 2026.
NTRA price target FAQ
What is the NTRA price target for 2030?
WallStSmart's Natera Inc 2030 base case is $178.39 per share, with a bull case of $441.05 and bear case of $90.84. The NPV of the base case discounted to today at 13% WACC is $101.14.
How is the Natera Inc 2030 stock forecast calculated?
The NTRA 2030 projection multiplies projected revenue by a growth-adjusted P/S multiple to derive enterprise value, subtracts projected net debt to get equity value, then divides by diluted shares outstanding accounting for dilution from stock-based compensation and equity raises.
Why does the NTRA price target account for dilution?
Natera Inc is projected to grow diluted share count from 143M to 148M by 2030 (a 3% increase) through stock-based compensation and capital raises. Ignoring this would inflate the price target by approximately 3%.
What is the analyst consensus on NTRA stock?
19 analysts cover NTRA with an average 12-month price target of $260.89. The 2030 projection extends this framework with longer-horizon assumptions including dilution and time value of money.